PLUR 10-Q Quarterly Report Dec. 31, 2014

PLURI INC.

10-Ks and 10-Qs

10-Q	Quarter ended Sept. 30, 2025
10-K	Fiscal year ended June 30, 2025
10-Q	Quarter ended March 31, 2025
10-Q	Quarter ended Dec. 31, 2024
10-Q	Quarter ended Sept. 30, 2024
10-K	Fiscal year ended June 30, 2024
10-Q	Quarter ended March 31, 2024
10-Q	Quarter ended Dec. 31, 2023
10-Q	Quarter ended Sept. 30, 2023
10-K	Fiscal year ended June 30, 2023
10-Q	Quarter ended March 31, 2023
10-Q	Quarter ended Dec. 31, 2022
10-Q	Quarter ended Sept. 30, 2022
10-K	Fiscal year ended June 30, 2022
10-Q	Quarter ended March 31, 2022
10-Q	Quarter ended Dec. 31, 2021
10-Q	Quarter ended Sept. 30, 2021
10-K	Fiscal year ended June 30, 2021
10-Q	Quarter ended March 31, 2021
10-Q	Quarter ended Dec. 31, 2020
10-Q	Quarter ended Sept. 30, 2020
10-K	Fiscal year ended June 30, 2020
10-Q	Quarter ended March 31, 2020
10-Q	Quarter ended Dec. 31, 2019
10-Q	Quarter ended Sept. 30, 2019
10-K	Fiscal year ended June 30, 2019
10-Q	Quarter ended March 31, 2019
10-Q	Quarter ended Dec. 31, 2018
10-Q	Quarter ended Sept. 30, 2018
10-K	Fiscal year ended June 30, 2018
10-Q	Quarter ended March 31, 2018
10-Q	Quarter ended Dec. 31, 2017
10-Q	Quarter ended Sept. 30, 2017
10-K	Fiscal year ended June 30, 2017
10-Q	Quarter ended March 31, 2017
10-Q	Quarter ended Dec. 31, 2016
10-Q	Quarter ended Sept. 30, 2016
10-K	Fiscal year ended June 30, 2016
10-Q	Quarter ended March 31, 2016
10-Q	Quarter ended Dec. 31, 2015
10-Q	Quarter ended Sept. 30, 2015
10-K	Fiscal year ended June 30, 2015
10-Q	Quarter ended March 31, 2015
10-Q	Quarter ended Dec. 31, 2014
10-Q	Quarter ended Sept. 30, 2014
10-K	Fiscal year ended June 30, 2014
10-Q	Quarter ended March 31, 2014
10-Q	Quarter ended Dec. 31, 2013
10-Q	Quarter ended Sept. 30, 2013
10-K	Fiscal year ended June 30, 2013
10-Q	Quarter ended March 31, 2013
10-Q	Quarter ended Dec. 31, 2012
10-Q	Quarter ended Sept. 30, 2012
10-K	Fiscal year ended June 30, 2012
10-Q	Quarter ended March 31, 2012
10-Q	Quarter ended Dec. 31, 2011
10-Q	Quarter ended Sept. 30, 2011
10-K	Fiscal year ended June 30, 2011
10-Q	Quarter ended March 31, 2011
10-Q	Quarter ended Dec. 31, 2010
10-Q	Quarter ended Sept. 30, 2010
10-K	Fiscal year ended June 30, 2010
10-Q	Quarter ended March 31, 2010
10-Q	Quarter ended Dec. 31, 2009

PROXIES

DEF 14A	Filed on June 30, 2025
DEF 14A	Filed on May 27, 2025
DEF 14A	Filed on June 25, 2024
DEF 14A	Filed on May 1, 2024
DEF 14A	Filed on April 27, 2023
DEF 14A	Filed on Feb. 27, 2023
DEF 14A	Filed on June 21, 2022
DEF 14A	Filed on April 27, 2022
DEF 14A	Filed on April 8, 2021
DEF 14A	Filed on May 20, 2020
DEF 14A	Filed on April 25, 2019
DEF 14A	Filed on April 3, 2018
DEF 14A	Filed on March 30, 2017
DEF 14A	Filed on April 4, 2016
DEF 14A	Filed on April 2, 2015
DEF 14A	Filed on March 31, 2014
DEF 14A	Filed on March 29, 2013
DEF 14A	Filed on March 22, 2012
DEF 14A	Filed on April 15, 2011

10-Q 1 zk1516129.htm 10-Q zk1516129.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2014

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from __________ to __________

Commission file number 001-31392

PLURISTEM THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

Nevada		98-0351734
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

MATAM Advanced Technology Park, Building No. 5, Haifa, Israel 31905

(Address of principal executive offices)

011-972-74-7108607

(Registrant’s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registration was required to submit and post such files).

Yes x No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

	Large accelerated filer o	Accelerated filer x
	Non-accelerated filer o (Do not check if a smaller reporting company)	Smaller reporting company o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes o No x

State the number of shares outstanding of each of the issuer’s classes of common stock as of the latest practicable date: 70,528,240 shares of common stock issued and outstanding as of January 29, 2015.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2014

(Unaudited)

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

As of December 31, 2014

U.S. DOLLARS IN THOUSANDS

(Unaudited)

INDEX

	Page

Interim Condensed Consolidated Balance Sheets	F - 2 - F - 3

Interim Condensed Consolidated Statements of Operations	F - 4

Interim Condensed Consolidated Statements of Comprehensive Loss	F - 5

Interim Condensed Statements of Changes in Equity	F - 6 - F - 7

Interim Condensed Consolidated Statements of Cash Flows	F - 8 - F - 9

Notes to Interim Condensed Consolidated Financial Statements	F - 10 - F - 20

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. Dollars in thousands (except share and per share data)

		December 31, 2014		June 30, 2014
	Note	Unaudited
ASSETS

CURRENT ASSETS:

Cash and cash equivalents		$	6,961	$	4,493
Short-term bank deposits			12,582		19,451
Restricted cash and short term bank deposits			691		4,914
Marketable securities	3		25,701		29,961
Account receivable from OCS			158		2,263
Other current assets			1,040		905
Total current assets			47,133		61,987

LONG-TERM ASSETS:

Long-term deposits and restricted deposits			271		304
Severance pay fund			723		901
Property and equipment, net			10,202		10,823
Other long-term assets			9		8
Total long-term assets			11,205		12, 036

Total assets		$	58,338	$	74,023

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F - 2

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED CONSOLIDATED BALANCE SHEETS

U.S. Dollars in thousands (except share and per share data)

		December 31, 2014			June 30, 2014
	Note	Unaudited
LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES

Trade payables		$	2,522		$	3,465
Accrued expenses			677			915
Deferred revenues			379			379
Advance payment from United Therapeutics			143			247
Other accounts payable			1,452			2,391
Total current liabilities			5,173			7,397

LONG-TERM LIABILITIES

Deferred revenues			2,657			2,847
Accrued severance pay			827			1,068
Other long-term liabilities			544			588
Total long-term liabilities			4,028			4,503

COMMITMENTS AND CONTINGENCIES	5

STOCKHOLDERS’ EQUITY

Share capital:	6
Common stock $0.00001 par value: Authorized: 200,000,000 shares Issued and outstanding: 70,494,863 shares as of December 31, 2014, 68,601,452 shares as of June 30, 2014			-(*	)		-(*	)
Additional paid-in capital			175,776			172,998
Accumulated deficit			(125,990	)		(113,834	)
Receivables on account of shares			(250	)		-
Other comprehensive income (loss)			(399	)		2,959
Total stockholders' equity			49,137			62,123

Total liabilities and stockholders' equity		$	58,338		$	74,023

(*)	Less than $1.

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F - 3

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)

U.S. Dollars in thousands (except share and per share data)

	Six months ended December 31,						Three months ended December 31,
	2014			2013			2014			2013
	Unaudited			Unaudited			Unaudited			Unaudited

Revenues	$	190		$	190		$	95		$	95
Cost of revenues		(7	)		(6	)		(4	)		(3	)
Gross profit		183			184			91			92
Research and development expenses		(11,121	)		(11,604	)		(5,385	)		(6,107	)
Less participation by the Office of the Chief Scientist and other parties		2,205			3,374			506			1,000
Research and development expenses, net		(8,916	)		(8,230	)		(4,879	)		(5,107	)
General and administrative expenses		(3,191	)		(3,804	)		(1,513	)		(1,975	)

Operating loss		(11,924	)		(11,850	)		(6,301	)		(6,990	)

Financial income (expense), net		(232	)		390			56			285

Net loss for the period	$	(12,156	)	$	(11,460	)	$	(6,245	)	$	(6,705	)

Loss per share:
Basic and diluted net loss per share	$	(0.17	)	$	(0.19	)	$	(0.09	)	$	(0.11	)

Weighted average number of shares used in computing basic and diluted net loss per share		69,610,528			60,379,352			70,070,509			61,510,550

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F - 4

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

U.S. Dollars in thousands

	Six months ended December 31,						Three months ended December 31,
	2014			2013			2014			2013
Net loss	$	(12,156	)	$	(11,460	)	$	(6,245	)	$	(6,705	)
Other comprehensive income (loss), net:
Unrealized gain (loss) on derivative instruments		(66	)		36			67			36
Changes in unrealized gains (losses) on available-for-sale marketable securities, net		(3,918	)		1,028			92			491
Reclassification adjustment of available-for-sale marketable securities gains (losses) realized in net loss, net		626			(165	)		171			(23	)
Other comprehensive income (loss)		(3,358	)		899			330			504
Total comprehensive loss	$	(15,514	)	$	(10,561	)	$	(5,915	)	$	(6,201	)

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F - 5

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

U.S. Dollars in thousands (except share data)

	Common Stock					Additional Paid-in		Accumulated Other Comprehensive		Accumulated			Total Stockholders’
	Shares		Amount			Capital		Income		Deficit			Equity
Balance as of July 1, 2013		59,196,617	$	(*	)	$	144,109	$	259	$	(86,902	)	$	57,466
Exercise of options and warrants by employees and consultants		7,405		(*	)		-		-		-			-
Exercise of warrants by investors and finders		1,942,474		(*	)		1,179		-		-			1,179
Stock based compensation to employees, directors and non-employee consultants		746,027		(*	)		2,336		-		-			2,336
Issuance of common stock under CHA agreement (Note 1d)		2,500,000		(*	)		10,414		-		-			10,414
Other comprehensive income, net		-		-			-		899		-			899
Net loss		-		-			-		-		(11,460	)		(11,460	)

Balance as of December 31, 2013		64,392,523	$	(*	)	$	158,038	$	1,158	$	(98,362	)	$	60,834

(*) Less than $1

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F - 6

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED STATEMENTS OF CHANGES IN EQUITY (UNAUDITED)

U.S. Dollars in thousands (except share data)

	Common Stock					Additional Paid-in		Receivables on account			Accumulated Other Comprehensive			Accumulated			Total Stockholders’
	Shares		Amount			Capital		of shares			Income (Loss)			Deficit			Equity
Balance as of July 1, 2014		68,601,452	$	(*	)	$	172,998		-		$	2,959		$	(113,834	)	$	62,123
Exercise of options by employees		3,000		(*	)		2		-			-			-			2
Exercise of warrants by investors and finders		822,734		(*	)		244		-			-			-			244
Stock based compensation to employees, directors and non-employee consultants		767,673		(*	)		1,754		-			-			-			1,754
Issuance of common stock in a private placement		200,000		(*	)		528					-			-			528
Stock based compensation to contractor		100,004		(*	)		250		(250	)		-			-			-
Other comprehensive loss, net		-		-			-		-			(3,358	)		-			(3,358	)
Net loss		-		-			-		-			-			(12,156	)		(12,156	)

Balance as of December 31, 2014		70,494,863	$	(*	)	$	175,776	$	(250	)	$	(399	)	$	(125,990	)	$	49,137

(*) Less than $1

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F - 7

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S. Dollars in thousands

	Six months ended December 31,
	2014			2013
CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss	$	(12,156	)	$	(11,460	)

Adjustments to reconcile net loss to net cash used in operating activities:

Depreciation		1,002			937
Loss on property and equipment		-			35
Accretion of discount, amortization of premium and changes in accrued interest of marketable securities		145			465
Gain from sale of investments of available-for-sale marketable securities		(197	)		(164	)
Stock-based compensation to employees, directors and non-employees consultants		1,754			2,336
Decrease (increase) in OCS receivables		2,105			(277	)
Decrease (increase) in other accounts receivable		181			(124	)
Decrease (increase) in prepaid expenses		(365	)		116
Increase (decrease) in trade payables		(772	)		488
Decrease in other accounts payable and accrued expenses		(417	)		(167	)
Decrease in deferred revenues		(190	)		(190	)
Decrease in advance payment from United Therapeutics		(104	)		(96	)
Increase in interest receivable on short-term deposits		(14	)		-
Linkage differences and interest on short and long-term deposits		65			1
Accrued severance pay, net		(63	)		(7	)
Net cash used by operating activities	$	(9,026	)	$	(8,107	)

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchase of property and equipment	$	(552	)	$	(1,169	)
Repayment of short-term deposits		11,072			7,961
Repayment of (investment in) long-term deposits		3			(3	)
Repayment of long-term restricted deposit		-			116
Proceeds from sale of available-for-sale marketable securities		2,409			2,963
Proceeds from redemption of available-for-sale marketable securities		301			583
Investment in available-for-sale marketable securities		(2,513	)		(7,904	)
Net cash provided by investing activities	$	10,720		$	2,547

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F - 8

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

U.S. Dollars in thousands

	Six months ended December 31,
	2014		2013
CASH FLOWS FROM FINANCING ACTIVITIES:

Exercise of options and warrants		246		1,179
Proceeds from issuance of common stock in a private placement		528		-
Net cash provided by financing activities	$	774	$	1,179

Increase (decrease) in cash and cash equivalents		2,468		(4,381	)
Cash and cash equivalents at the beginning of the period		4,493		9,007
Cash and cash equivalents at the end of the period	$	6,961	$	4,626

(a) Supplemental disclosure of cash flow activities:
Cash paid during the period for:
Taxes paid due to non-deductible expenses	$	17	$	35

(b) Supplemental disclosure of non-cash activities:
Purchase of property and equipment on credit	$	72	$	258
Issuance of common stock under CHA agreement	$	-	$	10,414

The accompanying notes are an integral part of the unaudited interim condensed consolidated financial statements.

F - 9

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 1:-GENERAL

Pluristem Therapeutics Inc., a Nevada corporation, was incorporated on May 11, 2001. Pluristem Therapeutics Inc. has a wholly owned subsidiary, Pluristem Ltd. (the “Subsidiary”), which is incorporated under the laws of the State of Israel. Pluristem Therapeutics Inc. and the Subsidiary are referred to as “Pluristem” or the “Company”.

The Company is a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions. The Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company's accumulated losses aggregated to $125,990 through December 31, 2014 and incurred a net loss of $12,156 for the six months ended December 31, 2014.

The Company plans to continue to finance its operations with sales of equity securities, entering into licensing technology agreements such as the United Therapeutics Corporation (“United”) and CHA Bio&Diostech (“CHA”) agreements, and from grants to support its research and development activity. In the longer term, the Company plans to finance its operations from revenues from sales of products.

c.	The Company’s shares of common stock are traded on the NASDAQ Capital Market under the symbol “PSTI”, and on the Tel-Aviv Stock Exchange under the symbol “PLTR”.

d.	License Agreements:

United Agreement

On June 19, 2011, the Company entered into an exclusive license agreement (the “United Agreement”) with United for the use of the Company's PLX cells to develop and commercialize a cell-based product for the treatment of Pulmonary Hypertension (“PAH”). The United Agreement provides that United will receive exclusive worldwide license rights for the development and commercialization of the Company's PLX cell-based product to treat PAH. The United Agreement further provides for the following consideration payable to the Company: (i) an upfront payment of $7,000 paid in August 2011, which includes a $5,000 non-refundable upfront payment and a $2,000 advance payment on the development; (ii) up to $37,500 upon reaching certain regulatory milestones with respect to the development of a product to treat PAH; (iii) reimbursement of up to $10,000 of certain of the Company's expenses if the Company establishes a GMP manufacturing facility in North America; (iv) reimbursement of certain costs in connection with the development of the product; and (v) following commercialization of the product, royalties at a mid-single digit percent and the purchase of commercial supplies of the developed product from the Company at a specified margin over the Company’s cost.

The United Agreement became effective on August 2, 2011, and will continue until the later of a few events, including termination of all patents relating to the collaboration, upon certain government action or if the parties do not develop any product under the United Agreement. United may unilaterally terminate the United Agreement at any time and without cause. In such event, United shall pay the Company certain costs and expenses of winding down any non-cancellable commitments made by the Company prior to the date of termination and cease all development activities in connection with the United Agreement.

CHA Agreement

On June 26, 2013, Pluristem entered into an exclusive license and commercialization agreement (the “CHA Agreement”) with CHA, for conducting clinical trials and commercialization of Pluristem's PLX-PAD product in South Korea in connection with two indications: the treatment of Critical Limb Ischemia, and Intermediate Claudication (the “Indications”). Under the terms of the CHA Agreement, CHA will receive exclusive rights in South Korea for conducting clinical trials with respect to the Indications, CHA will bear the costs of conducting the clinical trials for the agreed upon indications, and the Company will continue to retain rights to its proprietary manufacturing technology and cell-related intellectual property.

F - 10

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 1:-GENERAL (CONT.)

The first clinical study to be performed as part of the CHA Agreement will be a Phase II trial in Intermittent Claudication. This study was approved in November 2013 by South Korea’s Ministry of Food and Drug Safety.

Upon the first regulatory approval for a PLX product in South Korea, for the specified indications, Pluristem and CHA will establish an equally owned joint venture. The purpose of the joint venture will be to commercialize PLX cell products in South Korea.

Pluristem will be able to use the data generated by CHA to pursue the development of PLX product candidates outside of South Korea.

In addition, and as contemplated by the CHA Agreement, in December 2013, Pluristem and CHA executed the mutual investment pursuant to which Pluristem issued 2,500,000 shares of its common stock in consideration for 1,011,504 shares of CHA, which reflects total consideration to each of Pluristem and CHA of approximately $10,414. The investment in CHA shares is presented as “Marketable Securities” and classified as available-for-sale in accordance with ASC 320 – “Investments - Debt and Equity Securities”.

The CHA Agreement contains customary termination provisions, including in the event the parties do not reach an agreement upon development plan for conducting the clinical trials. Upon termination of this CHA Agreement, the license granted thereunder will terminate and all rights included therein will revert to the Company, whereupon the Company will be free to enter into agreements with any other third parties for the granting of a license in or outside South Korea or to deal in any other manner with such rights as it shall see fit at its sole discretion.

Each party had agreed to hold the other party’s shares for at least one year before selling any of such shares. The restriction period ended in December 2014. The parties also agreed to give an irrevocable proxy to the other party’s management with respect to the voting power of the shares issued.

NOTE 2:- BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

a.	Unaudited Interim Financial Information

The accompanying unaudited interim condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles ("GAAP") for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed).

For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2014.

Operating results for the three and six month periods ended December 31, 2014, are not necessarily indicative of the results that may be expected for the year ending June 30, 2015.

b.	Significant Accounting Policies

The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.

F - 11

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 2:- BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (CON.)

c.	Use of estimates

The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

d.	Fair value of financial instruments

The carrying amounts of the Company's financial instruments, including cash and cash equivalents, short-term and restricted bank deposits, trade payable and other accounts payable and accrued liabilities, approximate fair value because of their generally short term maturities.

The Company measures its investments in marketable securities and derivative instruments at fair value under ASC 820, “Fair Value Measurements and Disclosures” (“ASC 820”). Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. As a basis for considering such assumptions, ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:

Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 - Inputs other than Level 1 that are observable for the asset or liability, either directly or indirectly; and

Level 3 - Unobservable inputs for the asset or liability.

The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The Company categorized each of its fair value measurements in one of these three levels of hierarchy.

e.	Derivative financial instruments

The Company uses forward contracts and options strategies (“derivative instruments”) primarily to manage exposure to foreign currency. The Company accounts for derivatives and hedging based on ASC 815, “Derivatives and Hedging” (“ASC 815”). ASC 815 requires the Company to recognize all derivative instruments as either assets or liabilities on the balance sheet at fair value. The accounting for changes in the fair value (i.e., gains or losses) of derivative instruments depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, cash flow hedge, or a hedge of a net investment in a foreign operation.

If the derivative instruments meet the definition of a hedge and are so designated, depending on the nature of the hedge, changes in the fair value of such derivatives will either be offset against the change in fair value of the hedged assets, liabilities, or firm commitments through earnings, or recognized in other comprehensive income until the hedged item is recognized in the statement of operations. The ineffective portion of a derivative’s change in fair value is recognized in the statement of operations.

F - 12

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 2:- BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (CON.)

Cash Flow Hedges . The Company entered into forward contracts to hedge against the risk of overall changes in future cash flow from payments of payroll and related expenses denominated in New Israeli Shekels (“NIS”). The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2). The gain or loss on the effective portion of a cash flow hedge is initially reported as a component of accumulated other comprehensive income and subsequently reclassified into operating expenses in the same period or periods in which the payroll and related expenses are recognized, or reclassified into “Financial income (expenses), net”, if the hedged transaction becomes probable of not occurring. Any gain or loss after a hedge is no longer designated, because it is no longer probable of occurring or it is related to an ineffective portion of a cash flow hedge is recognized in the statement of operations immediately. As of December 31, 2014, the Company had forward contracts in place to hedge future payroll and related expenses in NIS of approximately $3,340, with a fair value of approximately $62 presented in “other current liabilities”. The net unrealized loss on the effective portion of these cash flow hedges was $66. The net loss realized in statement of operations during the three and six-month periods ended December 31, 2014, resulting from the cash flow hedge transactions, amounted to approximately $156 and $201, respectively. The forward contracts on the Company’s future NIS payroll and related expenses will settle by June 2015.

Fair Value Hedges . The Company entered into forward contracts designated as fair value hedges to hedge foreign currency risks for its investment denominated in currencies other than the U.S. dollar. The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2). Gains and losses on these contracts are recognized in "Financial income (expenses), net", along with the offsetting losses and gains of the related hedged items.

In connection with the investment in CHA shares (see Note 1d), an available-for-sale marketable security denominated in Korean Won, the Company entered into a forward contract to hedge against the foreign currency risk between the Korean Won and the U.S. dollar. The notional principal of this contract was $11,000. The forward contract expired on December 26, 2014, resulting in net gain of $59.

Other Derivatives . Other derivatives that are non-designated consist primarily of options strategies to minimize the risk associated with the foreign exchange effects of monetary assets and liabilities denominated in NIS. The Company measured the fair value of the contracts in accordance with ASC 820 (classified as level 2). The net gains (losses) recognized in “Financial income (expenses), net” during the three and six-month periods ended December 31, 2014, and 2013 were $59, $(139) and $(57), $(50), respectively.

F - 13

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 2:- BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (CON.)

f.	Accumulated other comprehensive income (loss) :

The components of accumulated other comprehensive income (loss) were as follows:

	Six months ended December 31, 2014 (Unaudited)
	Unrealized gains (losses) on marketable securities			Unrealized gains (losses) on cash flow hedges			Total
Balance as of July 1, 2014	$	2,936		$	23		$	2,959
Other comprehensive loss before reclassifications		(3,918	)		(267	)		(4,185	)
Amounts reclassified from accumulated other comprehensive loss		626			201			827
Net current-period other comprehensive income		(3,292	)		(66	)		(3,358	)
Balance as of December 31, 2014	$	(356	)	$	(43	)	$	(399	)

g.	Recent Accounting Pronouncement

In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09, "Revenue from Contracts with Customers" (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in “Revenue Recognition (Topic 605)”, and requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early adoption is not permitted. The Company is currently in the process of evaluating the impact of the adoption of ASU 2014-09 on its consolidated financial statements.

F - 14

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 3:- MARKETABLE SECURITIES

As of December 31, 2014, all of the Company’s marketable securities were classified as available-for-sale.

	December 31, 2014 (Unaudited)									June 30, 2014
	Amortized cost		Gross unrealized gain		Gross unrealized loss			Fair value		Amortized cost		Gross unrealized gain		Gross unrealized loss			Fair value
Available-for-sale - matures within one year:
Stock and index linked notes	$	18,043	$	1,054	$	(1,461	)	$	17,636	$	18,881	$	2,522	$	(23	)	$	21,380
Government debentures – fixed interest rate		357		3		(5	)		355		97		9		-			106
Corporate debentures – fixed interest rate		804		32		(34	)		802		452		54		-			506
	$	19,204	$	1,089	$	(1,500	)	$	18,793	$	19,430	$	2,585	$	(23	)	$	21,992
Available-for-sale - matures after one year through five years:
Government debentures – fixed interest rate		2,274		35		(31	)		2,278		2,595		98		(1	)		2,692
Corporate debentures – fixed interest rate		4,462		95		(49	)		4,508		4,906		263		(5	)		5,164
	$	6,736	$	130	$	(80	)	$	6,786	$	7,501	$	361	$	(6	)	$	7,856
Available-for-sale - matures after five years through ten years:
Corporate debentures – fixed interest rate		116		7		(1	)		122		94		19		-			113
	$	116	$	7	$	(1	)	$	122	$	94	$	19	$	-		$	113
	$	26,056	$	1,226	$	(1,581	)	$	25,701	$	27,025	$	2,965	$	(29	)	$	29,961

The following table presents gross unrealized losses and fair values for those investments that were in an unrealized loss position as of December 31, 2014 and June 30, 2014, and the length of time that those investments have been in a continuous loss position:

	Less than 12 months					12 months or greater
	Fair Value		Gross unrealized loss			Fair Value		Gross unrealized loss
As of December 31, 2014 (Unaudited)	$	13,447	$	(1,561	)	$	312	$	(18	)
As of June 30, 2014	$	851	$	(17	)	$	463	$	(12	)

The Company typically invests in highly-rated securities. When evaluating the investments for other-than-temporary impairment, the Company reviews factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, and the Company's intent to sell, or whether it is more likely than not it will be required to sell, the investment before recovery of the investment's amortized cost basis.

Based on the above factors, the Company concluded that unrealized losses on all available-for-sale securities were not other-than-temporary and no credit loss was present for any of its investments. As such, the Company did not recognize any impairment charges on outstanding securities during the three and six-month periods ended December 31, 2014.

F - 15

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 4:- FAIR VALUE OF FINANCIAL INSTRUMENTS

	December 31, 2014 (Unaudited)					June 30, 2014
	Level 1		Level 2			Level 1		Level 2
Marketable securities	$	16,417	$	9,284		$	20,530	$	9,431
Foreign currency derivative instruments		-		(178	)		-		(842	)
Total financial assets	$	16,417	$	9,106		$	20,530	$	8,589

	December 31, 2014 (Unaudited)					June 30, 2014
	Balance Sheet location		Fair Value			Balance Sheet location	Fair Value
Derivatives designated as a cash flow hedge instruments	Other current liabilities		$	(62	)	Other current assets	$	24
Derivatives not designated as hedge instruments	Other current liabilities		$	(116	)	Other current assets	$	23
Derivatives designated as a fair value hedge instruments		-		-		Other current liabilities		(889	)
Total			$	(178	)		$	(842	)

NOTE 5: - COMMITMENTS AND CONTINGENCIES

Commitments and contingencies that changed during the six months ended December 31, 2014, include the following:

a.	Decrease in the amount of $4,251 of cash pledged by the Company to secure its hedging transactions, credit line and bank guarantees.

The Company, through its Israeli subsidiary, participated in programs sponsored by the Israeli Government for the support of research and development activities. The Company is obligated to pay royalties to the OCS, amounting to 3%-4% of the sales of the products and other related revenues generated from such projects, up to 100% of the grants received, linked to the U.S. dollars and for grants received after January 1, 1999, also bearing interest at the rate of LIBOR. The obligation to pay these royalties is contingent on actual revenues and in the absence of such revenues, no payment is required.

Through December 31, 2014, total grants obtained aggregated to approximately $18,111, and total royalties paid and accrued amounted to $60. As of December 31, 2014, the Company's contingent liability in respect to royalties to the OCS amounted $18,051, not including LIBOR interest as described above.

F - 16

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 6: - STOCKHOLDERS' EQUITY

From July 2014 through December 2014, a total of 1,449,010 warrants were exercised via “cashless” exercise, resulting in the issuance of 675,067 shares of common stock to investors of the Company. In addition, 147,667 warrants were exercised for cash and resulted in the issuance of 147,667 shares of common stock to investors of the Company. The aggregate cash consideration received was $244.

b.	In October 2014, the Company issued 200,000 shares of common stock to an investor, in a private placement. The aggregate cash consideration received was $528.

In December 2014, the Company granted 100,004 restricted stocks to its new laboratories facility contractor. The restricted stocks are linked to performance milestones with respect to the building of new laboratories in the Company’s rented facility. These milestones have not been met yet. The fair value of the restricted stocks as of December 31, 2014 amounted to approximately $250.

d.	Options, warrants and restricted stock units to employees, directors and consultants:

Options to employees and directors:

A summary of the Company’s activity related to options granted to employees and directors under the Company’s 2003 and 2005 option plans is as follows:

	Six months ended December 31, 2014 (Unaudited)
	Number			Weighted Average Exercise Price		Weighted Average Remaining Contractual Terms (in years)		Aggregate Intrinsic Value Price
Options outstanding at beginning of period		1,862,099		$	3.73
Options exercised		(3,000	)	$	0.62
Options forfeited		-
Options outstanding at end of the period		1,859,099		$	3.73		2.62	$	778
Options exercisable at the end of the period		1,859,099		$	3.73		2.62	$	778
Options vested		1,859,099		$	3.73		2.62	$	778

Intrinsic value of exercisable options (the difference between the Company’s closing stock price on the last trading day in the period and the exercise price, multiplied by the number of in-the-money options) represents the amount that would have been received by the employees and directors option holders had all option holders exercised their options on December 31, 2014. This amount changes based on the fair market value of the Company’s common stock.

F - 17

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 6: - STOCKHOLDERS' EQUITY (CONT.)

d.	Options, warrants and restricted stock units to employees, directors and consultants (cont.):

Options and warrants to non-employees:

A summary of the activity related to options and warrants to consultants is as follows:

During the six month period ended December 31, 2014, there were no grants, exercises or forfeitures of options and warrants to or by non-employees consultants.

	Six months ended December 31, 2014 (Unaudited)
	Number		Weighted Average Exercise Price		Weighted Average Remaining Contractual Terms (in years)		Aggregate Intrinsic Value Price
Options and warrants outstanding at beginning of period		252,000	$	5.19
Options and warrants outstanding at end of the period		252,000	$	5.19		3.45	$	262

Options and warrants exercisable at the end of the period		252,000	$	5.19		3.45	$	262

Options and warrants vested and expected to vest		252,000	$	5.19		3.45	$	262

Compensation expenses related to options and warrants granted to consultants were recorded as follows:

	Six months ended December 31,				Three months ended December 31,
	2014		2013		2014		2013
Research and development expenses	$	1	$	2	$	-	$	-
General and administrative expenses		-		-		-		-
	$	1	$	2	$	-	$	-

F - 18

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 6: - STOCKHOLDERS' EQUITY (CONT.)

d.	Options, warrants and restricted stock units to employees, directors and consultants (cont.):

Restricted stock units to employees and directors:

During the six month period ended December 31, 2014, the Company granted restricted stock units to several of the Company's employees and directors.

The following table summarizes the activity related to unvested restricted stock units granted to employees and directors for the six-month period ended December 31, 2014 (Unaudited):

	Number
Unvested at the beginning of period		1,589,432
Granted		33,619
Forfeited		(18,405	)
Vested		(722,243	)
Unvested at the end of the period		882,403
Expected to vest after December 31, 2014		863,706

Compensation expenses related to restricted stock units granted to employees and directors were recorded as follows:

	Six months ended December 31,				Three months ended December 31,
	2014		2013		2014		2013
Research and development expenses	$	495	$	214	$	162	$	88
General and administrative expenses		1,143		2,103		441		1,055
	$	1,638	$	2,317	$	603	$	1,143

Unamortized compensation expenses related to restricted stock units granted to employees and directors to be recognized over an average time of approximately 2 years is $870.

F - 19

PLURISTEM THERAPEUTICS INC. AND ITS SUBSIDIARY

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

U.S. Dollars in thousands (except share and per share amounts)

NOTE 6: - STOCKHOLDERS' EQUITY (CONT.)

d.	Options, warrants, restricted stock and restricted stock units to employees, directors and consultants (cont.):

Restricted stock units to consultants:

During the six month period ended December 31, 2014, the Company granted restricted stock units to several consultants and service providers.

The following table summarizes the activity related to unvested restricted stock units granted to consultants for the six months ended December 31, 2014:

	Number
Unvested at the beginning of period		15,250
Granted		50,180
Forfeited		-
Vested		(45,430	)
Unvested at the end of the period		20,000
Expected to vest after December 31, 2014		20,000

Compensation expenses related to restricted stock units granted to consultants were recorded as follows:

	Six months ended December 31,				Three months ended December 31,
	2014		2013		2014		2013
Research and development expenses	$	77	$	17	$	57	$	16
General and administrative expenses		38		-		34		-
	$	115	$	17	$	91	$	16

F - 20

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward - Looking Statements

This quarterly report on Form 10-Q contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws, and is subject to the safe-harbor created by such Act and laws. Forward-looking statements may include statements regarding our goals, beliefs, strategies, objectives, plans, including product and technology developments, future financial conditions, results or projections or current expectations. In some cases, you can identify forward-looking statements by terminology such as “may,” “will,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential” or “continue,” the negative of such terms, or other variations thereon or comparable terminology. These statements are merely predictions and therefore inherently subject to known and unknown risks, uncertainties, assumptions and other factors that may cause actual results, performance levels of activity, or our achievements, or industry results to be materially different from those contemplated by the forward-looking statements. Such forward-looking statements appear in this Item 2 – “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” and may appear elsewhere in this quarterly report on Form 10-Q and include, but are not limited to, statements regarding the following:

·	the expected development and potential benefits from our products in treating various medical conditions;

the exclusive license agreements we entered into with United Therapeutics Corporation (United) and CHA Bio&Diostech (CHA) (United Agreement and CHA Agreement, respectively) and clinical trials to be conducted according to such agreements;

·	the prospects of entering into additional license agreements, or other forms of cooperation with other companies and medical institutions;

·	our pre-clinical and clinical trials plans, including the completion of recruitment processes and timing of conclusion of certain milestones and trials;

·	achieving regulatory approvals, including under accelerated paths;

·	receipt of future funding from the Office of the Chief Scientist of Israel (OCS);

·	developing capabilities for new clinical indications of placenta expanded cells (PLX);

·	the potential market demand for our products;

·	our expectations regarding our short- and long-term capital requirements;

·	our outlook for the coming months and future periods, including but not limited to our expectations regarding future revenue and expenses; and

·	information with respect to any other plans and strategies for our business.

Our business and operations are subject to substantial risks, which increase the uncertainty inherent in the forward-looking statements contained in this report. In addition, historic results of scientific research, clinical and preclinical trials do not guarantee that the conclusions of future research or trials would not suggest different conclusions. Also, historic results referred to in this periodic report would be interpreted differently in light of additional research, clinical and preclinical trials results. Except as required by law, we undertake no obligation to release publicly the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Further information on potential factors that could affect our business is described under the heading “Risk Factors” in Part I, Item 1A, of our Annual Report on Form 10-K for the fiscal year ended June 30, 2014. Readers are also urged to carefully review and consider the various disclosures we have made in that report.

As used in this quarterly report, the terms “we”, “us”, “our”, the “Company” and “Pluristem” mean Pluristem Therapeutics Inc. and our wholly owned subsidiary, Pluristem Ltd., unless otherwise indicated or as otherwise required by the context.

Overview

We are a bio-therapeutics company developing off-the-shelf allogeneic cell therapy products for the treatment of multiple ischemic and inflammatory conditions, with our lead indications focusing on cardiovascular, orthopedic, pulmonary, hematological, and women’s health diseases. Our patented PLX (PLacental eXpanded) cells function as a platform that releases a number of therapeutic proteins in response to various local and systemic inflammatory and ischemic signals, generated by the patient’s own body. PLX cells are grown using our proprietary 3D micro-environment technology that produces a product that requires no tissue matching prior to administration.

We were incorporated as a Nevada corporation in 2001. We have a wholly owned subsidiary in Israel called Pluristem Ltd. We operate in one segment and our operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies.

Our strategy is to develop and produce cell therapy products for the treatment of multiple disorders using several methods of administration, such as intravenous and intramuscular injections. We plan to execute this strategy independently, using our own personnel, and through relationships with research and clinical institutions or in collaboration with other companies, such as United and CHA. We have built a Good Manufacturing Practices (GMP) grade facility and we are planning to have in-house production capacity to grow clinical-grade PLX cells in commercial quantities.

Our focus for 2015 is to make significant progress in our clinical pipeline and shorten the time to market our first product. We intend to leverage the new regulatory environments in Europe and Japan that now offer unique opportunities for accelerated paths to bring new products to the market. These new pathways create substantial opportunities for us and for the cell therapy industry as a whole. We will explore these accelerated pathways for several of our current clinical indications, such as critical limb ischemia (CLI), as well as for carefully selected hematologic indications, which represent substantial unmet needs that we hope to address with our second product. We will continue developing placenta-derived cell therapy products that we anticipate will lead to significant improvement in the lives of patients, and expect to demonstrate the real-world impact and value of our pipeline, technology platform and commercial-scale manufacturing capacity. We made progress in our Phase II intermittent claudication trial, a randomized, double blind, placebo controlled, multinational study. We added sites in South Korea to this trial, which was already underway in Israel, U.S. and Germany. As of today, we have 23 active clinical sites, and expect to complete recruitment of this Phase II trial in 2015. We also anticipate that our partner, United, will complete an ongoing Phase I trial of PLX-PAD cells in pulmonary arterial hypertension, which will potentially lay the groundwork for a Phase II study. We plan to continue the progress toward achieving regulatory approvals for our phase I/II Preeclampsia study, study and advance phase II/III study in an orthopedic indication. and phase I/III critical limb ischemia study.

RESULTS OF OPERATIONS – SIX AND THREE MONTHS ENDED DECEMBER 31, 2014 COMPARED TO SIX AND THREE MONTHS ENDED DECEMBER 31, 2013.

Revenues

Revenues for the six and three month periods ended December 31, 2014, and for the six and three month periods ended December 31, 2013, were $190,000 and $95,000, respectively. All such revenues are derived from the United Agreement.

The Company estimated the performance period of the development of approximately 8 years as of December 31, 2014. The license fee will be recognized on a straight line basis as revenue over the estimated development period.

Research and Development Expenses, Net

Research and development expense, net (costs less participation and grants by the OCS and other parties) for the six months ended December 31, 2014 increased by 8% from $8,230,000 for the six months ended December 31, 2013 to $8,916,000. This increase is attributed to increase in stock-based compensation expenses related to our employees, an increase in our salaries due to, among other things, an increase of 5 employees as compared to the average number of employees in the six months ended December 31, 2013, and a decrease in the OCS participation due to the timing in which the OCS approval was granted. This increase is offset by a decrease in materials consumption and a decrease in payments to consultants and subcontractor.

Research and development expense, net, for the three months ended December 31, 2014 decreased by 4% from $5,107,000 for the three months ended December 31, 2013 to $4,879,000. This decrease is attributed to a decrease in materials consumption and a decrease in payments to consultants and subcontractor, offset by a decrease in the OCS participation, due to the timing in which the OCS approval was granted, and an increase in stock-based compensation expenses related to our employees.

General and Administrative Expenses

General and administrative expenses for the six months ended December 31, 2014 decreased by 16% from $3,804,000 for the six months ended December 31, 2013 to $3,191,000, mainly due to a decrease in stock-based compensation expenses related to our directors and officers and attributable to the timing of the grant of the restricted stock units (RSUs), offset by an increase in salaries due to, among other things, hiring 4 new employees since December 2013.

General and administrative expenses for the three months ended December 31, 2014 decreased by 23% from $1,975,000 for the three months ended December 31, 2013 to $1,513,000, mainly due to a decrease in stock-based compensation expenses related to our employees, directors and officers, offset by an increase in salaries due to, among other things, an increase of 5 employees as compared to the average number of employees in the three months ended December 31, 2013.

Financial Expense, Net

Financial expense, net, increased from a net income of $390,000 for the six months ended December 31, 2014 to a net expense of $232,000 for the six months ended December 31, 2014, mainly due to an increase in exchange rates expenses, related to the strength of the U.S. dollar against the New Israeli Shekel (NIS), in the six months ended December 31, 2014. This increase is offset by an increase in gains related to our sale of our marketable securities.

Financial expense, net, increased from a net income of $285,000 for the three months ended December 31, 2014 to a net income of $56,000 for the three months ended December 31, 2014, mainly due to an increase in exchange rate expenses, related to the strength of the U.S. dollar against the NIS, in the three months ended December 31, 2014. This increase is offset by an increase in gains related to our sale of our marketable securities.

Net Loss

Net loss for the six and three month periods ended December 31, 2014 was $12,156,000 and $6,245,000, respectively, as compared to net loss of $11,460,000 and $6,705,000 for the six and three month periods ended December 31, 2013, respectively. The changes were due to the increased expenses, as described above. Net loss per share for the six and three month periods ended December 31, 2014 was $0.17 and $0.09, respectively, as compared to $0.19 and $0.11 for the six and three month periods ended December 31, 2013.

For the six and three month periods ended December 31, 2014 and December 31, 2013, we had weighted average shares of common stock outstanding of 69,610,528, 70,070,509 and 60,379,352, 61,510,550 respectively, which were used in the computations of net loss per share for the six and three-month periods.

The increase in weighted average common shares outstanding reflects the issuance of additional shares, mainly the shares issued under an At Market Issuance Sales Agreement during February, March, and June 2014, as well as shares issued as a result of exercise of warrants and options, shares issued under a private placement in October 2014, and issuances of RSUs to employees and consultants.

Liquidity and Capital Resources

As of December 31, 2014, our total current assets were $47,133,000 and total current liabilities were $5,173,000. On December 31, 2014, we had a working capital surplus of $41,960,000, stockholders' equity of $49,137,000 and an accumulated deficit of $125,990,000. We finance our operations and plan to continue doing so from our existing cash, issuances of our securities, licensing fees and other payments under licensing agreements, and funds from grants from the OCS.

Cash and cash equivalents as of December 31, 2014 amounted to $6,961,000 compared to $4,626,000 as of December 31, 2013. Cash balances changed in the six months ended December 31, 2014 and 2013 for the reasons presented below.

Operating activities used cash of $9,026,000 in the six months ended December 31, 2014, compared to $8,107,000 for the six months ended December 31, 2013. Cash used in operating activities in the six months ended December 31, 2014 and 2013 consisted primarily of payments of salaries to our employees, and payments of fees to our consultants, suppliers, subcontractors, and professional services providers including the costs of clinical studies, offset by an OCS grant.

Investing activities provided cash of $10,720,000 in the six months ended December 31, 2014, compared to $2,547,000 for the six months ended December 31, 2013. The investing activities in the six months ended December 31, 2014 consisted primarily of the withdrawal of $11,072,000 of short term deposits and proceeds of $2,710,000 from the sale and redemption of marketable securities, offset by investing $2,513,000 in marketable securities and the purchase of property and equipment in the amount of $552,000. The investing activities in the six months ended December 31, 2013 consisted primarily of the withdrawal of $7,961,000 of short term deposits and proceeds of $3,546,000 from the sale and redemption of marketable securities, offset by investing $7,904,000 in marketable securities and the purchase of property and equipment in the amount of $1,169,000.

Financing activities generated cash of $774,000 during the six months ended December 31, 2014, compared to $1,179,000 for the six months ended December 31, 2013. The cash generated in the six months ended December 31, 2014 from financing activities is from exercises of warrants and options by shareholders, and proceeds from shares of our common stock issued in a private placement. The cash generated in the six months ended December 31, 2013 from financing activities was from exercises of warrants by shareholders.

In October 2014, we issued 200,000 shares of our common stock to an investor in a private placement. The aggregate cash consideration received was $528,000. These cash proceeds will be used for the building of new laboratories in our rented facility.

In December 2014, we issued 100,004 shares of restricted stock to our new laboratories facility contractor. The restricted stock is linked to performance milestones with respect to the building of new laboratories in our rented facility. These milestones have not been met yet. The fair value of the restricted stock on the grant date amounted to approximately $255,000.

During the six months ended December 31, 2014, we received cash of approximately $3,985,000 from the OCS towards our research and development expenses. According to the OCS grant terms, we are required to pay royalties at a rate of 3% - 4% on sales of products and services derived from technology developed using this and other OCS grants until 100% of the dollar-linked grants amount plus interest are repaid. In the absence of such sales, no payment is required. During the six months ended December 31, 2014, we paid $5,692 in royalties to the OCS.

As of today, the currency of our financial portfolio is mainly in U.S. dollars and we use forward and options contracts in order to hedge our exposures to currencies other than the U.S. dollar. For more information, please see Item 7A. - “Quantitative and Qualitative Disclosures About Market Risk” in our Annual Report of Form 10-K filed on September 11, 2014.

We have an effective Form S-3 registration statement, filed under the Securities Act of 1933, as amended (Securities Act) with the Securities and Exchange Commission (SEC) using a “shelf” registration process. Under this shelf registration process, we may, from time to time, sell common stock, preferred stock and warrants to purchase common stock, and units of two or more of such securities in one or more offerings up to a total dollar amount of $200 million.

Outlook

We have accumulated a deficit of $125,990,000 since our inception in May 2001. We do not expect to generate any revenues from sales of products in the next twelve months. Our products will likely not be ready for sale for at least three years, if at all. Our cash needs will increase in the foreseeable future. We expect to generate revenues, which in the short and medium terms will unlikely exceed our costs of operations, from the sale of licenses to use our technology or products, as we have in the United Agreement. Our management believes that we may need to raise additional funds before we have cash flow from operations that can materially decrease our dependence on our existing cash and other liquidity resources. We are continually looking for sources of funding, including non-diluting sources such as the OCS grants, sales of our common stock or sales of the marketable securities we hold, as well as the CHA shares we hold.

We believe that we have sufficient cash to fund our operations for at least the next 12 months.

Off Balance Sheet Arrangements

We have no off balance sheet arrangements.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures - We maintain a system of disclosure controls and procedures that are designed for the purposes of ensuring that information required to be disclosed in our SEC reports is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer (CEO) and our Chief Financial Officer (CFO) as appropriate to allow timely decisions regarding required disclosures.

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our CEO and our CFO, of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended. Based on that evaluation, our CEO and CFO concluded that our disclosure controls and procedures are effective.

Changes in Internal Control Over Financial Reporting - There has been no change in our internal control over financial reporting during the second quarter of fiscal 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

In October 2014, we issued 200,000 shares to an investor, resulting in net proceeds of $528,000. These cash proceeds will be used for the building of new laboratories in our rented facility.

In December 2014, we issued 100,004 shares of restricted stock to our building contractor. The restricted stock are linked to performance milestones with respect to the building of new laboratories in our rented facility.

In December 2014, we granted an aggregate of 12,706 RSUs to consultants for services rendered.

The above issuances and sales were exempt under Section 4(a)(2) of the Securities Act or Regulation S promulgated under the Securities Act.

Item 5. Other Information

On February 5, 2015, Mr. Boaz Gur-Lavie and our board of directors mutually agreed that Mr. Gur-Lavie will cease to be our Chief Financial Officer and Secretary, effective immediately. The determination was based on personal reasons and not as a result of any disagreement of Mr. Gur-Lavie with the Company. Mr. Yaky Yanay, our Chief Operating Officer and President, was also appointed as our Chief Financial Officer and Secretary on February 5, 2015.

On February 5, 2015, our board of directors also resolved to increase its total number of directors by one and nominate Mr. Yaky Yanay as a director, effective immediately. Currently, Mr. Yanay is not, and is not expected to be, a member of any committee of the board of directors. Neither Mr. Yanay nor any family member of his, has any material interest, direct or indirect, in any transaction, or proposed transaction in which the amount involved in the transaction exceeded or exceeds $120,000.

Mr. Yanay’s compensation has not changed as a result of his nomination as a director and a Chief Financial Officer and Secretary. Information on Mr. Yanay’s compensation arrangements is described under Part III, Item 11, of our Annual Report on Form 10-K for the fiscal year ended June 30, 2014.

Item 6. Exhibits.

31.1*	Rule 13a-14(a) Certification of Chief Executive Officer.

31.2*	Rule 13a-14(a) Certification of Chief Financial Officer.

32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350.

32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350.

101 *	The following materials from our Quarterly Report on Form 10-Q for the quarter ended December 31, 2014 formatted in XBRL (eXtensible Business Reporting Language): (i) the Interim Condensed Consolidated Balance Sheets, (ii) the Interim Condensed Consolidated Statements of Operations, (iii) the Interim Condensed Consolidated Statements of Comprehensive Loss, (iv) the Interim Condensed Statements of Changes in Equity, (v) the Interim Condensed Consolidated Statements of Cash Flows, and (vi) the Notes to Interim Condensed Consolidated Financial Statements, tagged as blocks of text and in detail.

*Filed herewith.

** Furnished herewith.

SIGNATURES

In accordance with the requirements of the Securities Exchange Act of 1934, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PLURISTEM THERAPEUTICS INC.

By: /s/ Zami Aberman

Zami Aberman, Chief Executive Officer

(Principal Executive Officer)

Date: February 5, 2015

By: /s/ Yaky Yanay

Yaky Yanay, Chief Financial Officer, Secretary, Chief Operating Officer and President

(Principal Financial Officer and Principal Accounting Officer)

Date: February 5, 2015

TABLE OF CONTENTS

Part I - Financial Information Item 1. Financial Statements Note 1:-general Note 1:-general (cont.)Note 2:- Basis Of Presentation and Significant Accounting Policies Note 2:- Basis Of Presentation and Significant Accounting Policies (con.)Note 3:- Marketable Securities Note 4:- Fair Value Of Financial Instruments Note 5: - Commitments and Contingencies Note 6: - Stockholders' Equity Note 6: - Stockholders' Equity (cont.)Item 2. Management S Discussion and Analysis Of Financial Condition and Results Of Operations Item 4. Controls and Procedures Part II - Other Information Item 2. Unregistered Sales Of Equity Securities and Use Of Proceeds Item 5. Other Information Item 6. Exhibits

PLUR 10-Q Quarter ended Dec. 31, 2014